KHAN Technology Transfer Fund II
Overview
KHAN Technology Transfer Fund II is an early-stage life sciences venture fund that focuses on creating value through cooperative drug development partnerships with academic innovators in Europe, targeting first-in-class therapies for markets with a high unmet medical need.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Revier Therapeutics | Aug 2026 | Seed | Lead |
| KyDo Therapeutics | Sep 2025 | Seed | Co-investor |
| iDEL Therapeutics | Mar 2026 | Seed | Co-investor |
| Nemea Therapeutics, Inc. | Nov 2025 | Pre Seed | Co-investor |
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is KHAN Technology Transfer Fund II based?
KHAN Technology Transfer Fund II is headquartered in Dortmund, Germany.
When was KHAN Technology Transfer Fund II founded?
KHAN Technology Transfer Fund II was founded in 2025.
How many portfolio companies does KHAN Technology Transfer Fund II have?
KHAN Technology Transfer Fund II has 4 portfolio companies in Caplight's dataset.
What are some companies in KHAN Technology Transfer Fund II's portfolio?
Portfolio companies visible on Caplight include Revier Therapeutics, KyDo Therapeutics, iDEL Therapeutics, Nemea Therapeutics, Inc..
What was KHAN Technology Transfer Fund II's most recent investment shown here?
KHAN Technology Transfer Fund II's most recent investment in this portfolio sample was in Revier Therapeutics in 2026.
What sectors does KHAN Technology Transfer Fund II focus on?
KHAN Technology Transfer Fund II focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences.
What company stages does KHAN Technology Transfer Fund II focus on?
KHAN Technology Transfer Fund II typically invests at the Early stage.
What is KHAN Technology Transfer Fund II's AUM?
KHAN Technology Transfer Fund II's assets under management are estimated between $141.7M and $141.7M.